62 related articles for article (PubMed ID: 36422094)
1. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line
Cho JH
Expert Rev Anti Infect Ther; 2024 Mar; ():1-7. PubMed ID: 38459869
[TBL] [Abstract][Full Text] [Related]
2. P-CAB
Jiang Y; Zhang R; Fang Y; Zhao R; Fu Y; Ren P; Zhan Q; Shao M
Therap Adv Gastroenterol; 2024; 17():17562848241241223. PubMed ID: 38751605
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan: A randomized, controlled, multicenter study.
Liu HN; Wang R; Cao Y; Xian F; Bi XJ; Wu DJ; Wang B; Wang XW; Lan CH
Clin Transl Gastroenterol; 2024 Apr; ():. PubMed ID: 38557975
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
Cho YK; Kim JH; Kim HS; Kim TO; Oh JH; Choi SC; Moon JS; Lee SK; Jung SW; Kim SS; Jung HK; Lee SP; Cheon GJ; Park MI; Jung HY; Ko KH; Sung IK; Lee SH; Lee JY; Lee ST; Rhee PL; Kim N; Hong SJ; Kim HJ; Kim GH; Lee KJ; Kim SK; Shin WG; Lee OY
Aliment Pharmacol Ther; 2023 Jan; 57(1):72-80. PubMed ID: 36314172
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study.
Jeon HK; Kim GH; Cheon YI; Shin SC; Lee BJ
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834761
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic exploration of various combinations of tegoprazan immediate and delayed-release formulations.
Park S; Yang E; Kim B; Kwon J; Jang IJ; Lee SH
Br J Clin Pharmacol; 2023 Sep; 89(9):2877-2887. PubMed ID: 37170677
[TBL] [Abstract][Full Text] [Related]
7. Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?
Choi HH
Gut Liver; 2023 Sep; 17(5):668-669. PubMed ID: 37712188
[No Abstract] [Full Text] [Related]
8. Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study.
Fekadu S; Kibru S; Tesfaye S; Egeno T; Tamiso A; Engiso H; Deyno S
Gut Pathog; 2024 Apr; 16(1):23. PubMed ID: 38678267
[TBL] [Abstract][Full Text] [Related]
9. Newer, Older, and Alternative Agents for the Eradication of
Buzás GM; Birinyi P
Antibiotics (Basel); 2023 May; 12(6):. PubMed ID: 37370265
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection.
Park CH; Park JH; Jung YS
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00632. PubMed ID: 37561041
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
Zhang M; Pang M; Zhang M
Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for
Park CH; Song MJ; Jung BW; Park JH; Jung YS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36422094
[TBL] [Abstract][Full Text] [Related]
15. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Park CH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1911-1918. PubMed ID: 35816283
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
